CVE-2007-6763
Description
SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.
Severity
HIGH
CVSS v3
8.8
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · source nvd
Exploit chance (EPSS)
1.320%
chance of exploitation in the next 30 days
higher than 71.4% of scored CVEs · 2026-11-17
CISA KEV
Not listed
Public exploit code
None public
Exploit references (NVD and CNA): 0
Metasploit modules: 0
Nuclei templates: 0
Weakness
- CWE-20: Improper Input Validation
Timeline
- 2019-07-31Published by the CNA17:08 UTC
Affected products
Products listed as vulnerable. Upgrade to the version under "Fixed in", or a later one.
| Product | Vulnerable versions | Fixed in |
|---|---|---|
| sas sas_drug_development | before 32drg02fixed in 32drg02 | 32drg02 |
References
Get more CVE data from the API.
curl 'https://api.contrastcyber.com/cve_lookup/CVE-2007-6763'curl 'https://api.contrastcyber.com/cve_risk_score/CVE-2007-6763'curl 'https://api.contrastcyber.com/cve_exploit/CVE-2007-6763'curl 'https://api.contrastcyber.com/cve_products/CVE-2007-6763'
Sources
- Vulnerability data from the National Vulnerability Database (NIST) and the CVE Program. CVE records: Copyright © 1999-2026, The MITRE Corporation, used under the CVE Program Terms of Use. CVE® is a registered trademark of The MITRE Corporation.
- CWE definitions: Copyright © 2006-2026, The MITRE Corporation, used under the CWE Terms of Use. CWE is a trademark of The MITRE Corporation.
- OWASP Top 10 categories by the OWASP Foundation (CC BY 3.0).
- EPSS scores by FIRST.org EPSS, used with attribution.
- KEV catalog and SSVC decisions by CISA.
- Advisory data from the GitHub Advisory Database through OSV.dev (CC BY 4.0).
- Exploit metadata from the Exploit Database (GPL-2.0-only, metadata only).
- Nuclei template names from nuclei-templates (MIT).